Mirowski M, Wierzbicki R
Zakład Biochemii Instytutu Badania Srodowiska i Bioanalizy Akademii Medycznej w Lodzi.
Postepy Hig Med Dosw. 1991;45(1-2):119-27.
This article contains a survey of works, published in the last few years on plasminogen activators inhibitors in neoplastic tissues. These inhibitors belong to a heterogenous group of proteins, having different molecular weights and specific ways of acting. They exemplify immunological relationship to known inhibitors of fibrinolysis from normal tissues--i.e. the inhibitors from endothelial cells--(PAI-1) and placental inhibitor--(PAI-2). To PAI-1 type belong: acid-stabile inhibitor of fibrinolysis with Mr 50,000 from HTC hepatoma cells in rats, acid-labile inhibitor Mr 42,770 produced by HepG2 human hepatoma cells; the inhibitor with Mr 54,000 from HT 1080 human cells from fibrosarcoma and single-chain acid-stabile inhibitor with Mr 50,000 from MJZJ melanoma cells. In PAI-2 type we can mention the inhibitor with Mr 47,000 from U-937 histiocytic lymphoma cells.
本文包含了对过去几年发表的关于肿瘤组织中纤溶酶原激活物抑制剂的研究综述。这些抑制剂属于一类异质性蛋白质,具有不同的分子量和特定的作用方式。它们体现了与正常组织中已知纤溶酶原激活物抑制剂(即内皮细胞来源的抑制剂(PAI-1)和胎盘来源的抑制剂(PAI-2))的免疫学关系。属于PAI-1类型的有:大鼠HTC肝癌细胞产生的分子量为50,000的酸稳定型纤溶酶原激活物抑制剂、人肝癌细胞HepG2产生的分子量为42,770的酸不稳定型抑制剂、人纤维肉瘤细胞HT 1080产生的分子量为54,000的抑制剂以及黑色素瘤细胞MJZJ产生的分子量为50,000的单链酸稳定型抑制剂。属于PAI-2类型的有:组织细胞淋巴瘤细胞U-937产生的分子量为47,000的抑制剂。